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Summary
The immune system is able to specifically target antigen-
expressing cancer cells. The promise of immunotherapy
was to eliminate cancer cells without harming normal tis-
sue and, therefore, with no or very few side effects. Im-
munotherapy approaches have, for several decades, been
tested against several tumours, most often against malig-
nant melanoma. However, although detectable immune re-
sponses have regularly been induced, the clinical outcome
has often been disappointing. The development of molecu-
lar methods and an improved understanding of tumour im-
munosurveillance led to novel immunotherapy approaches
in the last few years. First randomised phase III trials
proved that immunotherapy can prolong survival of pa-
tients with metastatic melanoma or prostate cancer. The de-
velopment in the field is very rapid and various molecules
(mainly monoclonal antibodies) that activate the immune
system are currently being tested in clinical trials and will
possibly change our treatment of cancer. The ultimate goal
of any cancer therapy and also immunotherapy is to cure
cancer. However, this depends on the elimination of the
disease originating cancer stem cells. Unfortunately, cancer
stem cells seem resistant to most available treatment op-
tions. Recent developments in immunotherapy may allow
targeting these cancer stem cells specifically in the future.
In this review, we summarise the current state of immuno-
therapy in clinical routine and the expected developments
in the near future.
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Immunosurveillance of cancer
The concept that elements of the immune system contribute
to cancer control was already proposed more than 100
years ago by the German pioneer in immunology and No-
bel Prize winner Paul Ehrlich. Although details of the dif-
ferent effector mechanisms of the immune system were un-
known at that time, he proposed that soluble factors that
he called ‘magic bullets’ are responsible for cancer control
[1]. In the 1950s, Burnet and Thomas formulated the im-
munosurveillance hypothesis [2]. They proposed that the
development of genetic alterations and early cancer are
very frequent events, but these early tumours never be-
come clinically apparent because they are destroyed by a
very efficient immune system. Their hypothesis was chal-
lenged by experimental data and clinical observations in
the 1970s. Patients that were treated with immunosuppress-
ive medication due to organ transplantations did not devel-
op solid tumours such as breast, colon or lung cancer at a
higher incidence than controls [3]. However, immunosup-
pressed patients had a highly increased incidence of ag-
gressive lymphomas associated with Epstein-Barr virus in-
fection [4].
Although the immune system does not play the central role
in the immunosurveillance as proposed by Burnet and Tho-
mas, more recent clinical studies provide evidence that cel-
lular immunity actually contributes to the control of car-
cinomas. Oncogenesis is a consequence of different genetic
alterations leading to uncontrolled cell proliferation and
metastasis. These genetic alterations encode proteins that
are quantitatively and/or qualitatively different to the pro-
teins expressed in the cell of origin. Therefore, these pro-
teins can serve as antigens and can be recognised by the
immune system. Tumour antigens that are selectively ex-
pressed by the tumour and are not expressed on normal
healthy tissues are ideal antigens for immunotherapy. Can-
cer testis antigens (CTA) are important representatives of
this group [5]. CTAs are only expressed on cancer cells and
in the testis. Since the testis is an immunologically priv-
ileged organ and does not express major histocompatibility
class I (MHC class I) molecules that allow antigen present-
ation, the cellular immune response is selective against the
cancer cells.
The immune response against cancer involves different ef-
fector mechanisms of adaptive and innate immunity, in-
cluding cytotoxic CD8+ T cells (CTLs), antibodies, natural
killer (NK) cells and also granulocytes and macrophages.
Experimental evidence, mainly from murine tumour mod-
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els, supports the view that anti-tumoural immunity is
largely mediated by CTLs [6]. Indeed, clinical studies in
patients suffering from malignant melanoma, ovarian can-
cer or colon cancer support this view. In all these different
cancer entities, the infiltration of CD8+ T cells in the tu-
mour correlates with improved prognosis [7].
Despite these effector mechanisms, the immune system
often fails to control the disease. Clinically documented
spontaneous remissions are very rare, but sometimes occur
in malignant melanoma. Why then is the immune control
of cancer often insufficient? There is a variety of different
very well defined escape mechanisms among tumours.
First, anti-tumoural immune responses select for cancer
cells with low immunogenicity by favouring loss or down-
regulation of specific antigens or antigen presenting mo-
lecules, a process known as cancer immunoediting [8].
Second, tumour cells may express cell-bound or soluble
immunosuppressive factors. Third, tumour blood vessels
lacking adhesion molecules, such as intercellular adhesion
molecule-1 (ICAM-1), may limit extravasation and infiltra-
tion of the tumour by CTLs [9]. Fourth, anti-tumoural im-
munity may be hampered by immunoregulatory mechan-
isms, such as regulatory T cells (Tregs), myeloid derived
suppressor cells and cytokines. The main function of Tregs
in healthy individuals is the suppression of an uncontrolled
immune activation to self-antigens, preventing autoimmu-
nity. In cancer patients, however, the frequency of these
Tregs in the circulation and especially at the tumour site,
is massively increased. Within the tumour environment of
most cancer types, Tregs suppress anti-tumoural immunity.
For example, the frequency of tumour infiltrating Tregs in
patients with ovarian cancer stage III and IV is a negative
prognostic factor [10]. In contrast, in some gastrointestinal
tumours, intratumoural Tregs seem to correlate with an im-
proved prognosis [11]. Therefore, determining the number
of tumour infiltrating Tregs may not be sufficient to predict
disease outcome for all tumour entities.
Immunotherapy in clinical routine
Immunotherapeutic strategies have been used for decades
in the field of oncology, although the mode of action has
not been completely solved yet. For example, Bacillus
Calmette-Guérin (BCG) instillations are used to treat non-
muscle invasive bladder cancer after surgical ablation [12].
It is assumed that BCG locally activates innate immunity,
decreasing the relapse rate. In addition, allogeneic haema-
topoietic stem cell transplantation (alloSCT) and the res-
ulting graft versus leukaemia effect (GvL) is mediated by
effectors of the adaptive immune system, such as T cells
and possibly NK cells. Moreover, part of the anti-tumour
effect of certain cytotoxic drugs may actually be mediated
by the immune system. Although apoptotic cells are often
removed by phagocytes without inducing an immune re-
sponse, certain cytotoxic drugs induce cell death that elicits
anti-tumour immune responses. This “immunogenic” cell
death has been described for anthracyclines and oxaliplatin
[13]. The activation of dendritic cells and immune effector
mechanisms depends on the exposure of cell death associ-
ated molecular patterns (CDAMPs). Some of the molecu-
lar pathways involved have been characterised recently and
include the exposure of calreticulin or the release of high-
mobility group box 1 (HMGB1) from dying cells [14, 15].
In contrast, despite testing different approaches in phase I
and II studies during the past decades, active immunother-
apy has only reached clinical routine in the last few years.
We now focus on the successful implementation of immun-
otherapies and their daily clinical use.
Passive immunotherapy
Passive immunotherapy describes the ex vivo generation of
effector molecules (e.g., antibodies) or effector cells (e.g.,
CTLs) that are then transferred to a patient. For approxim-
ately ten years, monoclonal antibodies (mAbs) have been
an integral part of the treatment of lymphoma and sol-
id tumours. mAbs may block important growth factors or
growth factor receptors on cancer cells or directly induce
apoptosis of the cancer cell. In addition, mAbs activate
parts of the immune system via the Fc-region of the anti-
body. Therefore, a main effector mechanism of these mAbs
is the antibody dependent cell-mediated cytotoxicity
(ADCC) that is executed by macrophages, NK cells and
probably granulocytes. Experimental evidence with Fc
gamma receptor-deficient mice supports the view that at
least part of the anti-tumoural effect of clinically relevant
antibodies, such as Rituximab (MabThera®), Trastuzumab
(Herceptin®) and Cetuximab (Erbitux®) is mediated via
ADCC [16]. In contrast to mAbs, adoptive T cell therapy
(ACT) did not reach clinical routine yet.
Active immunotherapy
Active immunotherapy describes the process of vaccina-
tion with a tumour antigen and the consequent activation
of the patient’s immune response. Different possibilities
to provide tumour antigen have been tested in preclinical
models and in clinical studies. These include injection of
purified tumour antigens, defined peptide fragments of spe-
cific antigens or the expression of the antigens by viral
vectors. Protein antigens and peptides have to be injected
together with adjuvants to improve the processing and
presentation of the antigen by dendritic cells (DCs) and
to provide a depot effect. Alternatively, DCs are loaded
with the antigen ex vivo prior to injection. So far, this
method seems most promising. Recently, in a large ran-
domised phase III study, men suffering from metastatic,
castration-resistant prostate cancer were treated with auto-
logous DCs generated from peripheral blood mononuclear
cells natured in vitro using a recombinant fusion protein
consisting of GM-CSF and the prostate-specific antigen
prostate acid phosphatase (PA2024). This cellular immun-
otherapy, called Sipuleucel-T (Provenge®), induced specif-
ic immune responses in these patients, reduced the risk of
death by 22% and improved median overall survival by 4.1
months compared to the placebo group [17].
Immunomodulation
In addition to the antigen-specific immunotherapies de-
scribed above, the immune system may also be activated
non-specifically. This can be achieved by modulation of
co-stimulatory and co-inhibitory molecules. The interac-
tion of B7 molecules (CD80, CD86) with cytotoxic T
lymphocyte antigen 4 (CTLA-4) leads to suppression of T
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cells. Targeting CTLA-4 with a blocking mAb (e.g., Ipilim-
umab, Yervoy®) will force B7 molecules to interact with
the co-stimulatory molecule CD28 leading to T cell activ-
ation. In two large phase III trials, treatment of metastatic
melanoma patients with Ipilimumab prolonged overall sur-
vival by approximately four months. Of note, Ipilimumab
was the first therapy for metastatic melanoma that signific-
antly improved overall survival [18]. Interestingly, Ipilim-
umab rarely induces objective clinical responses according
to response evaluation criteria in solid tumours (RECIST).
In some patients, tumour size even increased early after
therapy. This may be due to tumour infiltration by immune
cells or by oedema. Importantly, the immune system led
to a long-term stabilisation of the disease. However, the
unspecific immune activation did not only induce anti-
tumoural immunity but also autoimmunity, leading to
diarrhoea, hepatitis, skin toxicity and hypophysitis. The po-
tential of Ipilimumab is now under investigation in clinical
phase II/III studies for different solid tumours.
Novel developments
Modulating T cell activity by interfering with co-
stimulatory or co-inhibitory pathways
The hallmark study with Ipilimumab in advanced melan-
oma [18] created interest in the evaluation of further co-
inhibitory proteins, such as T cell immunoglobulin and
mucin domain-containing protein 3 (TIM-3), lymphocyte
activation gene 3 (LAG-3) and programmed death (PD)
family members. PD-1 is primarily expressed on activated
T and B cells. Similar to CTLA-4, the interaction of PD-1
with its ligands PD-L1 or PD-L2 limits T cell activation
to constrain autoimmune reactions. Constitutive signalling
via PD-1 on antigen-specific T cells was documented to in-
duce T cell anergy and exhaustion in chronic viral infec-
tions and cancer, resulting in a failure to control the disease
[19].
Figure 1
Examples of co-stimulatory and co-inhibitory molecules on T cells
suitable for targeting with agonistic and blocking antibodies,
respectively. CTLA-4, cytotoxic T lymphocyte antigen-4; PD-1,
programmed cell death 1; TIM-3, T cell immunoglobulin and mucin
domain-containing protein 3; LAG-3, lymphocyte activation gene 3;
ICOS, inducible T cell co-stimulator; GITR, glucocorticoid-induced
TNF family related gene; CD, cluster of differentiation.
We, and others, recently demonstrated that blocking PD-1
signalling results in improved tumour control in pre-clin-
ical mouse models [20]. In 2006, the first human anti-
PD-1 antibody was tested in a phase I trial with patients
suffering from refractory solid tumours [21]. Even though
patients with advanced disease resistant to conventional
treatment were included in this phase I study, tumour re-
gression was observed in some cases (one durable com-
plete response and two partial responses in a total of 39
patients). Objective responses correlated with lymphocyte
infiltration in metastatic tumours. In addition, lower tox-
icity has been reported compared to Ipilimumab. This cor-
relates well with a more moderate autoimmunity phenotype
of PD-1-/- mice compared to CTLA-4-/- mice [19]. These
promising results led to phase I trials with anti-PD1 and
anti-PD-L1 antibodies in advanced clear-cell renal cell car-
cinoma, melanoma, non-small cell lung cancer (NSCLC),
prostate cancer and colorectal cancer. Objective tumour re-
sponses were observed with either antibody at a frequency
of about 10-20%. Importantly, some of the treated patients
had a prolonged disease stabilisation rate. At least for the
activity of the anti-PD-1 antibody, the expression of its lig-
and PD-L1 on tumour cells seems to be a predictive factor
for response [22, 23]. Currently, four pharmaceutical com-
panies develop antibodies that block the PD-1 signalling
pathway.
Furthermore, comparable promising results have been
shown for blocking antibodies or small molecule inhibitors
against LAG-3, TIM-3 and B and T lymphocyte attenuator
(BTLA). Combination treatment regimens, e.g. parallel
blockade of CTLA-4 and PD-1, act synergistically in the
activation of anti-tumoural immunity and might be superior
to monotherapy in terms of efficacy and side effects [24].
In addition, T cell co-stimulatory receptors such as CD28
and the TNF receptor family members CD137, OX40,
GITR and CD27 may serve as potential targets for agonist-
ic mAbs in order to activate anti-tumoural T cell responses
(fig. 1). Unfortunately, data from a phase I clinical trial on
an agonistic CD28 mAb demonstrated severe treatment-re-
lated toxicities due to a cytokine-release syndrome [25].
In contrast, the TNF receptor family members seem prom-
ising targets for improving anti-tumoural immunity in pre-
clinical models. Administration of agonistic anti-mouse
CD137 mAb resulted in reduced tumour growth even in
poorly immunogenic tumours. Re-challenge experiments
in anti-CD137-treated mice demonstrated that these mice
developed memory cells specific for tumour-antigens and
were subsequently protected from further tumour growth.
Administration of agonistic anti-CD137 mAb even preven-
ted recurrence of primary tumours after resection and pre-
vented metastasis formation [26]. In addition, the combin-
ation of agonistic anti-CD137 mAb and Trastuzumab in
a HER-2 positive breast cancer model resulted in an en-
hanced activation of the immune system and improved tu-
mour control compared to Trastuzumab alone [27].
T cell-mediated anti-tumoural immunity can be induced
by administration of agonistic anti-OX40 mAbs or
OX40-ligand-IgG fusion proteins, as shown in several pre-
clinical studies. Agonistic anti-OX40 mAb had the most
potent anti-cancer effect in combination with chemother-
apy and irradiation [28]. More recently, it was demon-
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strated that dual treatment using agonistic anti-OX40 mAb
and IL-2 resulted in increased anti-tumoural immunity
against several types of cancer [29]. These promising res-
ults led to the development of human agonistic anti-OX40
mAbs that are currently being tested in early clinical trials.
Furthermore, agonistic anti-GITR mAbs reduced Treg cell
activity and enhanced tumour rejection and in parallel re-
duced Treg cell activity in pre-clinical tumour models [30].
Current evidence supports the view that CD27-signalling
improves anti-tumoural immunity as well. However, these
findings are controversial. Some pre-clinical studies
demonstrate that agonistic anti-CD27 mAbs effectively ac-
tivate immune cells to control or eliminate lymphomas,
leukemia and solid tumours. Consequently, the
CD27-targeting therapeutic strategy is currently evaluated
in a phase I trial for patients with haematological malignan-
cies and selected solid tumours. In contrast, we could re-
cently document in a murine tumour model that activation
of CD27 induces progression of solid tumours by inducing
regulatory Tregs [31].
In summary, many pre-clinical studies have demonstrated
that targeting co-stimulatory or co-inhibitory pathways
alone or in combination with conventional therapy in-
creases anti-tumoural immunity and may even eradicate
established tumours in some situations. Therefore, it is
expected that in addition to the already approved mAb
Ipilimumab, many new immunomodulating antibodies will
be used to treat cancer in the future.
Figure 2
Structure and assembly of next-generation chimeric antigen
receptors (CARs).
CARs are comprised of the variable portion (Fv) from an antibody
with a defined specificity for a tumour antigen linked via a
transmembrane domain (TM) to intracellular signaling domains
(SDs) from the T cell receptor (TCR)-complex (CD3ζ chain), as well
as one or several SDs from co-stimulatory receptors (e.g. CD28,
OX40, CD137). Consequently, T cells expressing genetically
engineered CARs can be activated independent of antigen-
presenting cells; recognition of tumour antigen by the Fv-portion
results in full activation of T cells.
Adoptive T cell therapy
ACT employs the transfusion of large numbers of auto-
logous or allogeneic T cells with high avidity for tumour
antigens. The source of tumour-specific T cells is either
naturally-occurring autologous T cells from the tumour mi-
croenvironment (e.g., tumour-infiltrating lymphocytes) or
blood or genetically engineered T cells expressing high af-
finity tumour-specific T cell receptors (TCRs) [32]. Main
problems in the clinical development of ACT were the
labour-intensive development of specific T cell clones or
T cell lines in vitro, their short half-life after transfer into
the patient and the need of an individual development of
T cells due to HLA-restriction. The in vivo half-life of
the transferred T cells could be increased after lymph-
odepletion before adoptive transfer. Lymphodepletion with
chemotherapy or irradiation may reduce immunosuppress-
ive cells and generate space in lymphoid organs to allow
a more efficient engraftment of the transferred cells. Ad-
optive T cell therapy after lymphodepletion showed object-
ive responses in heavily pre-treated melanoma patients [32,
33].
Advances in T cell engineering using lentiviral and retro-
viral vectors carrying genetically engineered TCRs expan-
ded the opportunities for ACT. Genetically engineered T
cells were shown to recognise and destroy solid tumours
expressing the cognate antigens. This resulted in clinical
studies testing the role of ACT using genetically engin-
eered T cells in tumours other than melanoma such as neur-
oblastoma, synovial cell sarcoma, leukaemia and lymph-
oma [34]. The high affinity TCRs expressed on genetically
engineered T cells are either of human or murine origin.
For example, TCR DNA sequences originating from a
tumour-reactive T cell of a cancer patient can be isolated
and cloned into autologous T cells from HLA-compatible
donors. Furthermore, human T cells can be engineered to
express mouse TCRs. T cells in human HLA transgenic
mice immunised with human melanoma antigens generated
TCRs with high avidity against tumour antigens. These
TCRs were cloned into autologous human T cells, which
were injected into melanoma patients and elicited a com-
plete response in 19% of the cases [35].
Another promising possibility to direct T cells to a given
tumour is the genetic engineering of a chimeric antigen re-
ceptor (CAR). CAR T cells express a so called “T-body”,
a receptor consisting of a recognition domain and a sig-
nalling domain from the humoral and cellular adaptive im-
mune system, respectively. In the majority of the cases, the
CAR consists of a single chain variable fragment (Fv) of
an mAb specific for a tumour antigen and an activating im-
mune receptor, such as the TCR-associated CD3ζ chain.
Next-generation CARs additionally contain co-stimulatory
sequences, e.g. the cytoplasmic domain of CD28 or OX40,
to allow full activation of the T cell (fig. 2). Upon binding
of the Fv to the tumour antigen, the T cell is activated
and elicits its effector function. Thereby, CAR T cells by-
pass the need of functional antigen processing and expres-
sion on MHC class I or II molecules on the surface of tu-
mour cells. In pre-clinical tumour models, first-generation
CAR T cells showed successful anti-tumoural activity, res-
ulting in tumour regression [36]. The safety of CAR ACT
could be demonstrated in phase I clinical trials, however,
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the outcomes regarding tumour control were rather disap-
pointing. CAR T cells did not efficiently migrate to tu-
mour sites and showed limited persistence, activation and
effector function in vivo. In contrast, long-term anti-tu-
moural activity of CAR T cells was demonstrated in one
clinical trial in which 19 patients with high-risk neuro-
blastoma were treated using ACT with T cells engineered
to express CARs directed against the GD2 antigen. In 3 of
11 patients, a complete remission was observed that was
associated with persistence of CAR T cells and improved
survival [37]. The positive outcomes concerning safety and
feasibility and the promising objective responses in this
clinical trial resulted in the development of next-genera-
tion CARs that are currently under investigation [38, 39].
For example, in B cell lymphoma patients, T cells contain-
ing a second-generation CAR equipped with a co-stimulat-
ory CD28 domain showed an improved in vivo-persistence
compared to T cells containing first-generation CARs only
targeting the CD19 antigen [39]. Subsequently, these next-
generation CARs preferentially targeting lymphoma and
leukaemia antigens were used in phase I and II clinical tri-
als. Third-generation CARs containing two co-stimulatory
signalling domains from CD28 and CD137 demonstrated
safety, long-term persistence and anti-tumour activity in
patients with lymphoma [40]. In a recent study, chronic
lymphocytic leukaemia (CLL) patients treated with a low
number of CAR T cells (1x105 CAR T cells / kg body
weight) targeting CD19 and containing the co-stimulatory
signalling domain of CD137 showed a complete remis-
sion. Furthermore, CAR-expressing T cells persisted more
than 6 months, expanded more than 1000-fold and showed
a CD19-specific immune response in the blood and bone
marrow (killing of >1000 CLL cells per CAR cell). Most
importantly, however, some of these CAR-T cells deve-
loped an effector memory phenotype allowing them to po-
tentially expand upon secondary encounter with CLL cells
and prevent relapse [41].
One of the major limitations of CAR ACT is that lymph-
odepletion with chemotherapy or irradiation and their as-
sociated side effects has to precede the transfer of CAR
T cells. Pre-clinical studies addressing this issue recently
demonstrated that CD19-specific CARs that constitutively
secrete IL-12 eradicate lymphoma even in the absence of a
pre-conditioning regimen [42].
Targeting cancer stem cells
Cancer stem cells (CSCs) are a subpopulation of cancer
cells that are thought to drive the growth of tumours, sim-
ilar to somatic stem cells that drive the growth of healthy
proliferative tissues (e.g., bone marrow, epithelia). CSCs
possess stem cell characteristics, i.e. dormancy/quiescence,
self-renewal and unlimited proliferative potential, and have
the ability to generate all the distinct malignant cell types
within the tumour. In addition, they are thought to be cap-
able of seeding to distant sites to initiate metastases.
Depending on the origin of the tumour, CSC frequencies
range from <1% to the majority of cells in the tumour.
Leukaemia CSCs, so-called leukaemia stem cells (LSCs),
were the first CSCs to be characterised and are among the
most well-defined CSCs. Subsequently, CSCs were found
in solid tumours as well, such as breast, ovarian, colon and
brain cancer [43, 44].
Cure of cancer implies the elimination of CSCs. However,
CSCs display increased resistance against chemotherapy,
irradiation and even targeted therapy. Several factors fa-
vour CSC resistance, such as the expression of high levels
of ABC pumps that expel small molecules and the local-
isation in hypoxic niches, preventing the accumulation of
reactive oxygen species after radiotherapy. Therefore, new
therapies that selectively destroy CSCs are needed (fig. 3).
Immunotherapy may be an attractive strategy to directly at-
tack CSCs, but prior to developing new treatments, a more
detailed understanding of the biology of CSCs and the dis-
tinctions from normal somatic stem cells is needed [45, 46].
First, methods need to be developed that allow prospective
isolation of live CSCs from bulk tumour mass as well as
isolation of somatic stem cells as their cognate healthy
counterparts. Surface molecules that distinguish CSCs
from bulk tumour cells have been found for various
haematological and solid tumours (table 1). However, these
molecules are rarely exclusively expressed by the CSC but
are markers for normal somatic stem cells as well, high-
lighting the necessity to define more specific molecules or
to use combinations.
Secondly, we need models that allow analysing and under-
standing differences in the biology of CSCs and somatic
stem cells with regards to cell survival, proliferation, differ-
entiation, responses to injury and drug resistance. Without
this knowledge, it will be impossible to design drugs tar-
geting pathways critical for CSC maintenance that are non-
toxic to normal somatic stem cells. Today, the most widely
used models for CSC propagation are murine xenograft as-
says analysing the repopulation of and serial transplant-
ation in immunodeficient mice (NOD/SCID mice; NSG
mice), as well as in vitro clonogenicity assays (long-term
cultures; spheroids). However, some caveats should be kept
in mind when analysing CSCs using these models, such as
Figure 3
Targeting cancer stem cells (CSCs) using immunotherapy.
As compared to the bulk of tumour cells, CSCs may also be
targeted using antibody-based therapies by blocking pathways
important for homing and engraftment (CD44), self-renewal (CD27),
protection against phagocytosis (CD47) and by delivering
radioactive compounds (IL-3Rα). In addition, strongly activated and
expanded cytotoxic CD8+ T cells (CTLs) specific for CSC antigens
are promising candidates for a potent and long-lasting elimination
of CSCs. Finally, forcing CSCs into the cell-cycle by breaking their
dormancy using proliferation-activating molecules, followed by
conventional cytotoxic chemotherapy, may represent an attractive
two-step strategy to eradicate CSCs.
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a) plasticity of the CSC state (CSC targeting is only an op-
tion if the CSC phenotype is stable), b) the experimental
procedures (species barrier, transplantation setting and cel-
lular stress) and c) the use of bona fide CSC markers (most
CSC markers such as CD133 are also widely expressed
in healthy tissues). These issues are comprehensively re-
viewed in [47].
Finally, we need to understand why most chemotherapeut-
ics effectively eradicate bulk tumour cells without affecting
CSCs. Patients achieving clinical remission from their can-
cer may harbour dormant, drug-resistant CSCs that persist
and cause disease relapse years or even decades later [48].
Therefore, developing methods to detect and quantify these
residual CSCs is essential to design more comprehensive
combinatorial or sequential treatment regimens.
Antibody targeting of cancer stem cells
mAbs against CD44, an adhesion molecule and E-selectin
ligand, markedly reduced human acute myeloid leukaemia
(AML) repopulation and led to absence of leukaemia in
serially xenotransplanted NOD/SCID mice. Anti-CD44
mAbs directly interfered with (LSC-niche interactions and
altered the LSC fate [49]. In a murine chronic myeloid
leukaemia (CML) model, the expression of CD44 on LSCs
was increased compared to haematopoietic stem cells
(HSCs), and CD44-deficient LSCs and LSCs pre-treated
with a blocking anti-CD44 mAb were unable to home to
and engraft in recipient bone marrow [50]. Several anti-
CD44 mAbs are now tested for human AML, breast cancer,
head and neck cancer and melanoma [51].
CD47, that interacts with signal-regulatory protein α
(SIRPα) on macrophages and inhibits macrophage-induced
phagocytosis, is normally expressed on circulating HSCs
to avoid phagocytosis. Weissman and colleagues demon-
strated that CD47 is overexpressed on mouse and human
leukaemia cells and LSCs to evade macrophage killing.
CD47 is an adverse prognostic factor in human AML and
a possible drug target on human AML LSCs [52]. Further-
more, CD47 was not only overexpressed in myeloid leuk-
aemias but also in acute lymphocytic leukaemia (ALL),
and targeting CD47 using mAbs in an ALL xenograft mod-
el eliminated the leukaemia, suggesting the elimination of
ALL LSCs. In addition, these authors showed that CD47 is
expressed on a variety of human solid tumours and CSCs,
e.g. bladder, ovarian, brain, breast, colon, hepatocellular
and prostate cancer, and that its expression is higher on tu-
mour cells than on normal tissue cells [53].
Recent work from our laboratory demonstrates that LSCs
may be targeted by blocking CD27 signalling. The TNF-
receptor family member CD27 is expressed on CML LSC
and CD27 signalling activated the canonical Wnt pathway,
induced LSC proliferation, increased differentiation to ma-
lignant granulocytes and promoted disease progression.
Blocking CD27 signalling by transplanting CD27-deficient
leukaemias or by mAb treatment reduced accumulation of
nuclear β-catenin in LSCs, delayed disease progression and
prolonged survival [54].
Another promising approach to target CSCs is the coupling
of mAbs to radioisotopes. Reilly and colleagues used a
mouse mAb specific for the IL-3Rα chain expressed on
AML LSCs, which was modified with a nuclear localiza-
tion signal and 111Indium. This mAb was internalised upon
binding to IL-3Rα and caused DNA double strand breaks
in AML cell lines and primary human AML cells [55].
Further promising strategies to directly attack CSCs using
mAbs aim at the interruption of signalling pathways es-
sential for stem cell self-renewal and maintenance, such
as the Wnt/Frizzled, Delta/Notch and Hedgehog/Patched
pathways [51].
Cellular therapy against cancer stem cells
AalloSCT and donor lymphocyte infusions (DLIs) are im-
munotherapies for high-risk leukaemia patients, which po-
tentially lead to cure of the disease, implying the elim-
ination of LSCs. The mechanisms underlying this phe-
nomenon have been termed graft versus leukaemia effect
(GvL). GvL is most probably mediated by minor
histocompatibility-specific CTLs as well as NK cells [56].
In a murine xenograft model of human AML, Bonnet and
colleagues were able to demonstrate that minor
histocompatibility-specific CTLs eliminate AML LSCs,
providing evidence that CTLs may represent a therapeutic
strategy to eliminate CSCs [57]. These findings were sup-
ported by a recent study in a murine CML model showing
that DLIs are able to block LSC engraftment and eradicate
leukaemia in combination with imatinib [58].
For solid tumours, several attempts to eradicate CSCs are
being investigated, including vaccination using CSCs fused
to DCs or CSC peptide-pulsed DCs to prime CTL re-
sponses [59], the induction of γδ T cells that eliminate
CSCs directly or via the secretion of IL-17 [60] and NK
cell-mediated CSC killing [61].
Breaking CSC dormancy using immunomodulation
Dormancy and quiescence are hallmarks of stem cells, pre-
serving self-renewal capability and preventing stem cell
exhaustion. Upon tissue injury, stem cells leave their
dormant state and begin to proliferate, giving rise to transit-
amplifying daughter cells as well as new stem cells (asym-
metric division). Since proliferating cells are more sensit-
ive to DNA damage-inducing chemotherapeutics and drugs
affecting the mitotic spindle, it was proposed to imply a
two-step therapeutic strategy by priming dormant CSCs
with proliferation-inducing compounds prior to conven-
tional or targeted chemotherapy. Today, several molecules
are known to induce proliferation of HSCs, such as IFN-
α, IFN-γ, G-CSF and arsenic trioxide [46, 62, 63]. Indeed,
until 2001, IFN-α was the standard therapy for newly dia-
gnosed CML, leading to long-term remissions in a signi-
ficant number of CML patients. The introduction of imat-
inib dramatically changed treatment of CML, however, it
has to be taken life-long, and CML often relapses after drug
discontinuation. Interestingly, in a French CML trial, the
only patients experiencing long-term remission after dis-
continuation of imatinib had been treated with IFN-α be-
fore [46]. These findings indicate that combination treat-
ment protocols may be a promising concept to eradicate
dormant CSCs.
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Concluding remarks
Immunotherapy is now part of clinical routine in the treat-
ment of some tumours and novel immunotherapies against
cancer will be available soon. New developments are ex-
pected in the field of modulating T cell activity by inter-
fering with co-stimulatory or co-inhibitory pathways and
in adoptive immunotherapy using CAR T cells. In recent
years, clinical trials in oncology have well documented that
only a small fraction of the treated patients profit from tar-
geted therapy with newly developed drugs or, very compar-
ably, from immunotherapy. Currently available data sug-
gest that only a small fraction of melanoma patients benefit
from Ipilimumab treatment, as indicated by long-term sta-
bilisation of the disease. In addition to the establishment of
novel therapeutic molecules, a main focus of investigation
must therefore lay on the establishment of predictive bio-
markers that allow selecting for patients who will respond
to a defined immunotherapy. Unfortunately, current clin-
ical developments in immunotherapy are not very focused
and the efficacy of the novel molecules is tested in unse-
lected patient populations in most or every tumour entity.
However, since immunotherapy may be considered a prime
example for targeted therapy, it is fundamental to charac-
terise and define the requirements for successful tumour
control, e.g. expression of tumour antigens on tumour cells,
persistence and fate of transferred CAR T cells and others.
The definition of predictive biomarkers will be crucial to
define the role of the currently available and the novel im-
munotherapy strategies for each tumour in the future.
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Figures (large format)
Figure 1
Examples of co-stimulatory and co-inhibitory molecules on T cells suitable for targeting with agonistic and blocking antibodies, respectively.
CTLA-4, cytotoxic T lymphocyte antigen-4; PD-1, programmed cell death 1; TIM-3, T cell immunoglobulin and mucin domain-containing protein
3; LAG-3, lymphocyte activation gene 3; ICOS, inducible T cell co-stimulator; GITR, glucocorticoid-induced TNF family related gene; CD, cluster
of differentiation.
Review article: Current opinion Swiss Med Wkly. 2013;143:w13734
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 10 of 12
Figure 2
Structure and assembly of next-generation chimeric antigen receptors (CARs). CARs are comprised of the variable portion (Fv) from an
antibody with a defined specificity for a tumour antigen linked via a transmembrane domain (TM) to intracellular signaling domains (SDs) from
the T cell receptor (TCR)-complex (CD3ζ chain), as well as one or several SDs from co-stimulatory receptors (e.g. CD28, OX40, CD137).
Consequently, T cells expressing genetically engineered CARs can be activated independent of antigen-presenting cells; recognition of tumour
antigen by the Fv-portion results in full activation of T cells.
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Figure 3
Targeting cancer stem cells (CSCs) using immunotherapy. As compared to the bulk of tumour cells, CSCs may also be targeted using antibody-
based therapies by blocking pathways important for homing and engraftment (CD44), self-renewal (CD27), protection against phagocytosis
(CD47) and by delivering radioactive compounds (IL-3Rα). In addition, strongly activated and expanded cytotoxic CD8+ T cells (CTLs) specific
for CSC antigens are promising candidates for a potent and long-lasting elimination of CSCs. Finally, forcing CSCs into the cell-cycle by
breaking their dormancy using proliferation-activating molecules, followed by conventional cytotoxic chemotherapy, may represent an attractive
two-step strategy to eradicate CSCs.
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